IDO1 and central nervous system cancer: We compared the therapeutic effects of RY103 with IDO1 selective inhibitor INCB, and TMZ, a standard chemotherapeutic agent for malignant glioma, as well as the combination of RY103 with TMZ in GL261 orthotopic glioma-bearing mice.